These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 19538162)

  • 21. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small-molecule correctors and stabilizers to target p53.
    Fallatah MMJ; Law FV; Chow WA; Kaiser P
    Trends Pharmacol Sci; 2023 May; 44(5):274-289. PubMed ID: 36964053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
    Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
    Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 oligomers: antagonizers of the guardian of the genome.
    Leslie PL; Zhang Y
    Oncogene; 2016 Dec; 35(48):6157-6165. PubMed ID: 27041565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
    Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
    Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
    Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
    Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
    Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
    Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the MDM2-p53 interaction for cancer therapy.
    Shangary S; Wang S
    Clin Cancer Res; 2008 Sep; 14(17):5318-24. PubMed ID: 18765522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
    Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
    J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
    Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
    Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
    Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mdmx promotes genomic instability independent of p53 and Mdm2.
    Carrillo AM; Bouska A; Arrate MP; Eischen CM
    Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.